Thelansis

Lantern Pharma Inc., an AI company pioneering cancer therapies, announces that the FDA has granted Fast Track Designation for its investigational drug, LP-184, to treat Glioblastoma. Currently in a Phase 1A clinical trial, LP-184 is being evaluated for safety and tolerability in various solid tumors, including GBM. Optimized through Lantern’s AI platform, RADR®, the drug aims to target mechanisms to combat challenging cancers. RADR® integrates over 100 billion data points, fueling Lantern’s drug portfolio and collaborations. Publish Date: 15-10-2024   Source: Lantern Pharma Inc. Glioblastoma (GBM) is the most aggressive among the diffuse gliomas originating from the astrocytic lineage. It ranks as the most prevalent malignant primary brain tumor, comprising 54% of all gliomas and 16% of primary brain tumors. GBM is classified as a malignant astrocytic tumors, earning a Grade IV designation according to the WHO classification. The exact cause of this disease remains unknown, exce

  Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company dedicated to developing gene therapies for retinal degenerative diseases, has announced a successful FDA meeting for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP). Based on the positive regulatory feedback received during the meeting, Nanoscope will begin the submission of a Biologics License Application (BLA) in the first quarter of 2025. This marks a significant step forward in the company’s mission to bring effective treatments to patients suffering from RP. Publish Date: 15-10-2024   Source: Nanoscope Therapeutics Inc. Retinitis pigmentosa (RP) is a hereditary degenerative condition of the retina characterized by night blindness and a gradual loss of peripheral vision, eventually leading to complete blindness. The primary malfunction typically occurs in the rod photoreceptors, causing them to deteriorate progressively. Subsequently, cone cells also perish, like

  Papillon Therapeutics Inc., a clinical-stage biotechnology company focused on developing multi-systemic genetic medicines to address the root causes of inherited diseases, has announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to their experimental treatment, PPL-001, for Friedreich’s ataxia. PPL-001 has previously received Orphan Drug designation, underscoring its potential as a significant therapeutic advancement for this rare disease. Publish Date: 15-10-2024   Source: Papillon Therapeutics Inc. Friedreich ataxia, a rare hereditary condition, initiates its course during childhood and results in a gradual nervous system deterioration, along with motor function impairments. Approximately 25% of individuals affected by Friedreich ataxia experience an unconventional variant where symptoms manifest after age 25. This disorder predominantly affects European, Middle Eastern, or North African individuals and is infrequently obs